Lack of tumor recognition by hTERT peptide 540-548-specific CD8+ T cells from melanoma patients reveals inefficient antigen processing

European Journal of Immunology

Volumn 31, Issue 9, 2001, Pages 2642-2651

  Ayyoub, Maha ^a,c   Migliaccio, Marco ^a   Guillaume, Philippe ^b   Liénard, Danielle ^a   Cerottini, Jean Charles ^a   Romero, Pedro ^b   Lévy, Frédéric ^a   Speiser, Daniel E ^a   Valmori, Danila ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Cytotoxic T lymphocyte; hTERT; Proteasome processing; Tumor immunity

Indexed keywords

CD8 ANTIGEN; EPITOPE; HLA A ANTIGEN; HUMAN TELOMERASE CATALYTIC SUBUNIT DERIVED PEPTIDE 540-548; PEPTIDE; PROTEASOME; RIBONUCLEOPROTEIN; TELOMERASE; TETRAMER; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL DIVISION; CELL LINE; CELL SELECTION; CELL STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR; ENZYME ACTIVE SITE; FLUORESCENCE; GENETIC TRANSFECTION; GERM LINE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; MELANOMA; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; T LYMPHOCYTE; TARGET CELL; TELOMERE;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELL LINE; CLONE CELLS; CYSTEINE ENDOPEPTIDASES; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES; FLOW CYTOMETRY; HLA-A ANTIGENS; HUMANS; MELANOMA; MULTIENZYME COMPLEXES; PEPTIDE FRAGMENTS; PROTEASOME ENDOPEPTIDASE COMPLEX; T-LYMPHOCYTES, CYTOTOXIC; TELOMERASE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034812048     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200109)31:9<2642::AID-IMMU2642>3.0.CO;2-6     Document Type: Article

References (32)

1. Tumor antigens recognized by T lymphocytes
2. T cell defined tumor antigens
3. Serological analysis of human tumor antigens: Molecular definition and implications
4. Human tumor antigens recognized by T cells
5. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
6. Naturally occurring HLA-A2 restricted CD8+ T cell response to the cancer testis antigen NYESO-1 in melanoma patients
7. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans
8. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
9. The telomerase reverse transcriptase: Components and regulation
10. Specific association of human telomerase activity with immortal cells and cancer
11. Applications of telomerase research in the fight against cancer
12. Extension of life-span by introduction of telomerase into normal human cells
13. Phenotypic analysis of antigen-specific T lymphocytes
14. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
15. Induction of telomerase activity and chromosome aberrations in human tumour cell lines following X-irradiation
16. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3
17. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide
18. Avoidance of self-reactivity results in skewed CTL responses to rare components of synthetic immunogens
19. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma
20. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide
21. Frequent cytolytic T cell responses to peptide MAGE-A10(254-262) in melanoma
22. Degradation of cell proteins and the generation of MHC class I-presented peptides
23. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells
24. Specificity of the proteasome and the TAP transporter
25. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients
26. Peptide-major histocompatibility complex class I complex: From the structural and molecular basis to pharmacological principles and therapeutic applications
27. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
28. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
29. Versatile retroviral vectors for potential use in gene therapy
30. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376
31. Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins
32. Using ubiquitin to follow the metabolic fate of a protein